HER2, p95HER2, and HER3 expression and treatment outcome of lapatinib plus capecitabine in HER2-positive, trastuzumab-refractory metastatic breast

被引：0
作者：
Han, S.
Ro, J.
Paquet, A.
Huang, W.
Weidler, J.
Lee, K. S.
Park, I.
Oh, D.
Im, S.
Kim, T.
机构：
[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[2] Natl Canc Ctr, Goyang Si, South Korea
[3] Monogram Biosci Inc, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.1088
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1088
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Impact of PIK3CA mutations and p95HER2 expression on the outcome of HER2-positive metastatic breast cancer patients treated with a trastuzumab-based therapy
    Fontana, Andrea
    Allegrini, Giacomo
    al Zoubi, Mazhar
    Collecchi, Paola
    Mazzanti, Chiara
    Stasi, Irene
    Lucchesi, Sara
    Bona, Eleonora
    Ferrarini, Ilaria
    Salvadori, Barbara
    Arrighi, Giada
    Marcucci, Lorenzo
    Filidei, Mario
    Orlandini, Cinzia
    Falcone, Alfredo
    Bevilacqua, Generoso
    Zavaglia, Katia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] HER2Δ16 expression in HER2-positive breast cancer
    De Yao, Jocelyn Torres
    Sun, Danyu
    Galehouse, Donna
    Shorten, Scott
    Haller, Nairmeen
    Rehmus, Esther Hoogland
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
    Murthy, R. K.
    Loi, S.
    Okines, A.
    Paplomata, E.
    Hamilton, E.
    Hurvitz, S. A.
    Lin, N. U.
    Borges, V.
    Abramson, V.
    Anders, C.
    Bedard, P. L.
    Oliveira, M.
    Jakobsen, E.
    Bachelot, T.
    Shachar, S. S.
    Mueller, V.
    Braga, S.
    Duhoux, F. P.
    Greil, R.
    Cameron, D.
    Carey, L. A.
    Curigliano, G.
    Gelmon, K.
    Hortobagyi, G.
    Krop, I.
    Loibl, S.
    Pegram, M.
    Slamon, D.
    Palanca-Wessels, M. C.
    Walker, L.
    Feng, W.
    Winer, E. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07) : 597 - 609
  • [24] HER2Δ16 expression in HER2-positive breast cancer
    De Yao, Jocelyn Torres
    Sun, Danyu
    Galehouse, Donna
    Shorten, Scott
    Haller, Nairmeen Awad
    Rehmus, Esther Hoogland
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
  • [25] HALT MBC: HER2 Suppression with the Addition of Lapatinib to Trastuzumab in HER2-Positive Metastatic Breast Cancer (LPT112515).
    Lin, N.
    Danso, M.
    David, A.
    Muscato, J.
    Ellis, C.
    DeSilvio, M.
    Garofalo, A.
    Nagarwala, Y.
    Winer, E.
    CANCER RESEARCH, 2011, 71
  • [26] HALT MBC: HER2 suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LPT112515)
    Lin, Nancy U.
    Danso, Michael A.
    David, Alice K.
    Muscato, Joseph J.
    Rayson, Daniel
    Houck, William A.
    Ellis, Catherine Elizabeth
    DeSilvio, Michelle
    Garofalo, Amanda
    Nagarwala, Yasir M.
    Winer, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Trastuzumab and lapatinib in HER2-positive metastatic colorectal cancer
    Biswas, Bivas
    Rastogi, Sameer
    Batra, Atul
    Ganguly, Sandip
    NATIONAL MEDICAL JOURNAL OF INDIA, 2016, 29 (04) : 219 - 220
  • [28] HER3 activation by MET contributes to trastuzumab resistance in HER2-positive breast cancer
    Hashimoto, Kenji
    Macaulay, Valentine
    Kong, Anthony
    CANCER RESEARCH, 2014, 74 (19)
  • [29] Lapatinib plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Watanabe, J.
    Hamauchi, S.
    Higashi, Y.
    Onozawa, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
    Madden, Rebecca
    Kosari, Sam
    Peterson, Gregory M.
    Bagheri, Nasser
    Thomas, Jackson
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2018, 56 (02) : 72 - 80
12345